Patents Examined by Bong-Sook Baek
  • Pyridazinone compound or its salt, and herbicide containing it
    Patent number: 10870638
    Abstract: A novel herbicide having remarkable herbicidal activities against undesired plants is provided. A pyridazinone compound represented by the formula (I) or its salt: wherein X is —O—, —S—, —SO—, —SO2— or —N(Y)—; Q is monocyclic aryl which may be substituted by Z, monocyclic heteroaryl which may be substituted by Z or the like; Y is a hydrogen atom or alkyl; Z is halogen, alkyl or the like; R1 is alkyl, alkenyl or the like; R2 is a hydrogen atom, alkyl or the like; R3 is halogen, hydroxy or the like; R4 is a hydrogen atom, alkyl or the like; and n is an integer of from 0 to 4.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 22, 2020
    Assignee: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Toshihiko Ueki, Ryu Yamada, Hisaki Tanaka
  • Bupropion as a modulator of drug activity
    Patent number: 10864209
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: December 15, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Tacrolimus for improved treatment of transplant patients
    Patent number: 10864199
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 15, 2020
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
    Patent number: 10842770
    Abstract: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: November 24, 2020
    Assignee: Teikoku Pharma USA, Inc.
    Inventor: Kiichiro Nabeta
  • Bio-active material composite, preparing method thereof and cosmetic composition containing the same
    Patent number: 10835461
    Abstract: Provided is a composite containing bio-active material stably combined with a rare-earth hydroxide compound having a layered structure. The bio-active materials in the composite are preserved in terms of long-term stability at high temperature of 50° C. or above and the composite maintained in the neutral pH condition to minimize side effects like latent toxicity, irritations, etc. Further, the present invention is useful for a skin-whitening, anti-wrinkle, or anti-aging cosmetic composition containing the composite.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: November 17, 2020
    Inventor: Bae Yong Kim
  • Bupropion as a modulator of drug activity
    Patent number: 10806710
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 20, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Combination of dextromethorphan and bupropion for treating depression
    Patent number: 10799497
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 13, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10786469
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: September 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10780066
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 22, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Quinolines that modulate SERCA and their use for treating disease
    Patent number: 10772881
    Abstract: Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. Also provided herein are methods of their use for modulating the activity of a sarcoplasmic/endoplasmic reticulum C2+ ATPase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 15, 2020
    Inventor: Russell Dahl
  • Modified release multi-layer tablet cannabinoid formulations
    Patent number: 10772837
    Abstract: The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 15, 2020
    Assignee: CannTab Therapeutics, Ltd
    Inventors: Robert Scott Lefler, Jeff Renwick, Joshi Laxminaraya
  • Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
    Patent number: 10765670
    Abstract: This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 8, 2020
    Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Franck Mouthon, Mathieu Charveriat
  • Extended release compositions comprising pyridostigmine
    Patent number: 10744093
    Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: August 18, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Siva Ram Kiran Vaka, Namdev B. Shelke, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
    Patent number: 10729643
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: August 4, 2020
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Quinolines as cytoprotective agents
    Patent number: 10730839
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 4, 2020
    Inventor: Russell Dahl
  • Anti-HCMV compositions and methods
    Patent number: 10723708
    Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: July 28, 2020
    Assignee: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
  • Sports health performance composition
    Patent number: 10688069
    Abstract: A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 23, 2020
    Assignee: REV Pharmaceuticals LLC
    Inventors: Beth Anne-Szkudlarek Brown, Anthony Lemus, Marnie L. Peterson
  • Particles containing branched polymers
    Patent number: 10675251
    Abstract: Particles comprising a branched polymer and either a block copolymer or a linear dendritic hybrid represent a category of useful materials. They may be used in for example drug delivery applications. They may be prepared by a method comprising the steps of: dissolving the branched polymer and block copolymer or linear dendritic hybrid, and optionally other component(s), in a solvent to form a solution; adding said solution to a different liquid; and removing said solvent to form a dispersion of co-precipitated particles.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: June 9, 2020
    Assignee: THE UNIVERSITY OF LIVERPOOL
    Inventors: Steve Rannard, Jane Ford, Hannah Rogers, Pierre Chambon, Marco Giardiello, Andrew Owen, Neil Kitteringham
  • Carcinoma diagnosis and treatment based on ODC1 genotype
    Patent number: 10655183
    Abstract: The present invention provides methods and kits a) for preventing and/or treating cancer (e.g., colorectal cancer, neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patient's whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: May 19, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA
    Inventors: Eugene Gerner, Patricia Thompson, Tracy Brooks, Jenaro Garcia-Huidobro
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10646492
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: May 12, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks